On December 8, Imexpharm was honored to be included in the Top 10 Best Annual Reports of 2022 in the medium-cap group at the Listed Companies Awards (VLCA). This award is an expanded version of the Annual Report Awards, a program with a longstanding tradition of supporting Vietnam’s stock market and its community of listed companies. The event is co-organized by the Ho Chi Minh City Stock Exchange (HOSE), the Hanoi Stock Exchange (HNX), and Báo Đầu tư (Vietnam Investment Review Newspaper).
In its 15th year, VLCA introduced significant improvements, including deeper evaluations of corporate governance among listed companies alongside assessments of annual reports and sustainability reports. By applying a dedicated set of criteria, the awards encourage the adoption of international corporate governance standards and practices, guiding businesses toward building a sustainable foundation for growth.
Out of nearly 600 listed companies on both exchanges, 40 were recognized across three categories: Annual Report, Corporate Governance Report, and Sustainability Report. Additionally, in each category, one company showing exceptional improvement was awarded the "Outstanding Progress" prize to acknowledge efforts in enhancing transparency. Notably, in 2022, for the first time, the organizers introduced an award for companies excelling in greenhouse gas emissions management under the Sustainability Report category.
This year, Imexpharm was honored to be named among the Top 10 Best Annual Reports of 2022 in the medium-cap group. This recognition, along with the Corporate Governance Report award, was announced in alphabetical order rather than by ranking scores, as in previous years. VLCA's acknowledgment highlights Imexpharm's continued efforts to enhance transparency in its annual reports, thereby increasing the company’s brand value and strengthening the trust of its shareholders, partners, and investors in its growth.
Becoming a business with a foundation of transparent and reliable governance for sustainable development is also a core goal for Imexpharm as it seeks deeper integration into global markets. Therefore, this award is truly a valuable milestone. With its steadily growing reputation and trust, Imexpharm is poised to achieve even greater breakthroughs and thrive sustainably in the future.